Simulations Plus Total Non-Operating Income/Expense 2010-2025 | SLP
Simulations Plus total non-operating income/expense from 2010 to 2025. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Simulations Plus Annual Total Non-Operating Income/Expense (Millions of US $) |
2024 |
$6 |
2023 |
$3 |
2022 |
$0 |
2021 |
$0 |
2020 |
$0 |
2019 |
$0 |
2018 |
$0 |
2017 |
$0 |
2016 |
$0 |
2015 |
$0 |
2014 |
$0 |
2013 |
$0 |
2012 |
$0 |
2011 |
$0 |
2010 |
$0 |
2009 |
$0 |
Simulations Plus Quarterly Total Non-Operating Income/Expense (Millions of US $) |
2025-02-28 |
$1 |
2024-11-30 |
$0 |
2024-08-31 |
$2 |
2024-05-31 |
$2 |
2024-02-29 |
$1 |
2023-11-30 |
$1 |
2023-08-31 |
$0 |
2023-05-31 |
$1 |
2023-02-28 |
$1 |
2022-11-30 |
$1 |
2022-08-31 |
$0 |
2022-05-31 |
$0 |
2022-02-28 |
$0 |
2021-11-30 |
$0 |
2021-08-31 |
$0 |
2021-05-31 |
$0 |
2021-02-28 |
$0 |
2020-11-30 |
$0 |
2020-08-31 |
$0 |
2020-05-31 |
$0 |
2020-02-29 |
$0 |
2019-11-30 |
$0 |
2019-08-31 |
$0 |
2019-05-31 |
$0 |
2019-02-28 |
$0 |
2018-11-30 |
$0 |
2018-08-31 |
$0 |
2018-05-31 |
$0 |
2018-02-28 |
$0 |
2017-11-30 |
$0 |
2017-08-31 |
$0 |
2017-05-31 |
$0 |
2017-02-28 |
$0 |
2016-11-30 |
$0 |
2016-08-31 |
$0 |
2016-05-31 |
$0 |
2016-02-29 |
$0 |
2015-11-30 |
$0 |
2015-08-31 |
$0 |
2015-05-31 |
$0 |
2015-02-28 |
$0 |
2014-11-30 |
$0 |
2014-08-31 |
$0 |
2014-05-31 |
$0 |
2014-02-28 |
$0 |
2013-11-30 |
$0 |
2013-08-31 |
$0 |
2013-05-31 |
$0 |
2013-02-28 |
$0 |
2012-11-30 |
$0 |
2012-08-31 |
$0 |
2012-05-31 |
$0 |
2012-02-29 |
$0 |
2011-11-30 |
$0 |
2011-08-31 |
$0 |
2011-05-31 |
$0 |
2011-02-28 |
$0 |
2010-11-30 |
$0 |
2010-08-31 |
$0 |
2010-05-31 |
$0 |
2010-02-28 |
$0 |
2009-11-30 |
$0 |
2009-08-31 |
$0 |
2009-05-31 |
$0 |
2009-02-28 |
$0 |
Sector |
Industry |
Market Cap |
Revenue |
Computer and Technology |
Computer Software |
$0.657B |
$0.070B |
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|